ERYtech Pharma Receives Orphan Drug Designation By The FDA For ERY-ASP In Acute Myeloid Leukemia
4/2/2014 9:40:13 AM
LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that its lead product GRASPA®/ERY-ASP1 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML), an aggressive form of blood cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by